The Ectodomain Shedding of E-cadherin by ADAM15 Supports ErbB Receptor Activation

Por Najy, Abdo J., Day, Kathleen C., Day, Mark L.
Publicado em 2008

ADAM15 Disintegrin Is Associated with Aggressive Prostate and Breast Cancer Disease

Por Kuefer, Rainer, Day, Kathleen C, Kleer, Celina G, Sabel, Michael S, Hofer, Matthias D, Varambally, Sooryanarayana, Zorn, Christoph S, Chinnaiyan, Ami M, Rubin, Mark A, Day, Mark L
Publicado em 2006

Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer

Por Grivas, Petros D, Day, Kathleen C, Karatsinides, Andreas, Paul, Alyssa, Shakir, Nazia, Owainati, Iya, Liebert, Monica, Kunju, Lakshmi P, Thomas, Dafydd, Hussain, Maha, Day, Mark L
Publicado em 2013

ADAM15 Is Functionally Associated with the Metastatic Progression of Human Bladder Cancer

Por Lorenzatti Hiles, Guadalupe, Bucheit, Amanda, Rubin, John R., Hayward, Alexandra, Cates, Angelica L., Day, Kathleen C., El-Sawy, Layla, Kunju, L. Priya, Daignault, Stephanie, Lee, Cheryl T., Liebert, Monica, Hussain, Maha, Day, Mark L.
Publicado no PLoS One (2016)

HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone

Por Day, Kathleen C., Hiles, Guadalupe Lorenzatti, Kozminsky, Molly, Dawsey, Scott J., Paul, Alyssa, Broses, Luke J., Shah, Rajal, Kunja, Lakshmi P., Hall, Christopher, Palanisamy, Nallasivam, Daignault-Newton, Stephanie, El-Sawy, Layla, Wilson, Steven James, Chou, Andrew, Ignatoski, Kathleen Woods, Keller, Evan, Thomas, Dafydd, Nagrath, Sunitha, Morgan, Todd, Day, Mark L.
Publicado no Cancer Res (2016)

A Randomized Phase 2 Trial of Gemcitabine/Cisplatin With or Without Cetuximab in Patients With Advanced Urothelial Carcinoma

Por Hussain, Maha, Daignault, Stephanie, Agarwal, Neeraj, Grivas, Petros D., Siefker-Radtke, Arlene O., Puzanov, Igor, MacVicar, Gary R., Levine, Ellis Glenn, Srinivas, Sandy, Twardowski, Przemyslaw, Eisenberger, Mario A., Quinn, David I., Vaishampayan, Ulka N., Yu, Evan Y., Dawsey, Scott, Day, Kathleen C., Day, Mark L., Al-Hawary, Mahmoud, Smith, David C.
Publicado em 2014

HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: Implications for efficacy of adjuvant trastuzumab

Por Ithimakin, Suthinee, Day, Kathleen C., Malik, Fayaz, Zen, Qin, Dawsey, Scott J., Bersano-Begey, Tom F., Quraishi, Ahmed A., Ignatoski, Kathleen Woods, Daignault, Stephanie, Davis, April, Hall, Christopher L., Palanisamy, Nallasivam, Heath, Amber N., Tawakkol, Nader, Luther, Tahra K., Clouthier, Shawn G., Chadwick, Whitney A., Day, Mark L., Kleer, Celina G., Thomas, Dafydd G., Hayes, Daniel F., Korkaya, Hasan, Wicha, Max S.
Publicado em 2013